A new publication dated August 17, 2026 discusses bradykinin in the context of a case report. The article, titled "From Sight to Stridor: Recurrent Angioedema in Systemic Lupus Erythematosus Associated With Complement Activation," appears in The American Journal of Case Reports.
The publication is listed under research involving bradykinin, which remains an unapproved compound used in research settings. No efficacy or treatment outcomes are described in the information provided.
This entry reflects the appearance of the publication itself rather than any summary of its findings. Readers interested in the full content of the case report can access it through the journal listing.
For general background on bradykinin, including its classification and research status, readers can consult the compound overview.